CDSCO is the apex regulatory body for medical devices, pharmaceuticals, and cosmetics entering the Indian market. All these products are regulated to ensure their safety and effectiveness as well as safeguard the patients and consumers. A CDSCO license is required to manufacture or import medical devices, pharmaceuticals, and cosmetics in India. This license is granted only after the regulatory officials check certain parameters. Only with a CDSCO approval can medical devices, pharmaceuticals, and cosmetics be legally sold in India. Selling these regulated products without CDSCO approval in India will attract legal and regulatory consequences. In this blog, we will discuss penalties for selling products without CDSCO approval in India.
What is CDSCO?
The Central Drugs Standard Control Organisation (CDSCO) under the Directorate General of Health Services, Ministry of Health and Family Welfare in India, is the regulatory body for medical devices, cosmetics, and pharmaceuticals in India. Similar to the Food and Drug Administration of the US, the CDSCO oversees that all medical devices, cosmetics, and drugs sold in India are effective and safe. CDSCO monitors and controls the registration and sale of medical devices, cosmetics, and drugs in India. Basically, it regulates the approval, manufacturing, and marketing of medical devices, pharmaceuticals, and cosmetics in India. Thus, CDSCO plays a crucial role in protecting public health and delivering improved healthcare.
It is mandatory for any company seeking to manufacture or import medical devices, drugs, and cosmetics for sale or distribution to obtain a license from the CDSCO. By implementing the best regulatory practice and exploiting scientific excellence, this regulatory body aims to ensure potent and quality products are available in the Indian market.
The Drug Controller General of India is the governing body of CDSCO. The CDSCO has two arms: Center Licensing Authority and State Licensing Authority. These arms are vested with different levels of power. Compliance with multiple regulations is essential for registering medical devices, drugs, and cosmetics with CDSCO. Notably, there will be penalties and regulatory consequences for selling products without CDSCO approval in India.
Products requiring CDSCO approval for manufacture and import in India
CDSCO regulates a wide range of products to ensure safety, efficacy, and quality:
- Pharmaceuticals (Drugs & APIs): All new drugs, fixed‑dose combinations, vaccines, blood products as well as bulk drugs and formulations require CDSCO approval. CDSCO drug manufacturing license is mandatorily required to manufacture drugs in India. Form 25 is a license issued for the manufacturing of non-biological drugs. Form 28 is the license for manufacturing of biological drugs. The CDSCO license to import drugs is issued on Form 10.
- Medical Devices and In‑Vitro Diagnostics (IVDs): All medical devices notified under the Medical Device Rules, 2017 (e.g., stents, pacemakers, diagnostic kits) and IVD reagents and kits require CDSCO approval. CDSCO MD5 manufacturing license is required to manufacture Class A and B medical devices and IVDs. Additionally, CDSCO MD9 manufacturing license is required to manufacture Class C and D medical devices and IVD. Moreover, CDSCO MD15 import license is required to import all classes of medical devices and IVDs.
- Cosmetics: CDSCO grants COS-8 license for manufacturing cosmetics in India. CDSCO grants COS-2 license to import cosmetics into India.
What activities are considered illegal to do without CDSCO approval in India?
We have listed some of the activities considered illegal without CDSCO approval in India.
- Manufacturing drugs or APIs: Producing formulations or bulk drugs without a valid drug manufacturing license.
- Manufacturing medical devices: Manufacturing Class A–D devices without the proper CDSCO medical device manufacturing license.
- Importing drugs, vaccines, or blood products: Importing APIs, finished formulations, vaccines, or biologics without a proper CDSCO drug import license.
- Importing medical devices: Bringing medical devices into India without a proper CDSCO medical device import license.
- Manufacturing cosmetics: Manufacturing cosmetics without proper CDSCO cosmetics manufacturing license.
- Importing cosmetics: Importing cosmetics without a CDSCO cosmetics import license.
- Selling or distributing unapproved products: Marketing, distributing, or supplying drugs, devices, or cosmetics that lack CDSCO approval.
- Clinical trials without permission: Conducting trials of new drugs or devices without CDSCO authorization.
- Mislabeling or false claims: Selling products with misleading labels, unapproved therapeutic claims, or without proper CDSCO registration.
Penalties and regulatory consequences for selling products without CDSCO approval in India
- Product seizure and confiscation: Selling unapproved drugs, devices, or cosmetics can lead to immediate seizure of stock by regulatory inspectors. Authorities may confiscate all related materials, including packaging and promotional content. This action prevents further distribution and protects public health from unsafe products. Seized goods are often destroyed or retained as evidence in legal proceedings. Such seizures can cause significant financial losses and reputational damage to the company.
- Business suspension or closure: Operating without CDSCO approval can result in suspension of manufacturing or import. Regulators may order temporary or permanent closure of facilities engaged in illegal activity. This disrupts supply chains and halts revenue streams for the business. Closure orders are often accompanied by public notices, damaging brand credibility. Reinstating operations requires lengthy compliance procedures and regulatory scrutiny.
- Criminal prosecution: Individuals responsible for unauthorized sales may face criminal charges under the Drugs & Cosmetics Act, 1940. Charges can include fraud, negligence, and endangering public health. Court proceedings may involve both company executives and operational staff. Convictions can lead to imprisonment, depending on the severity of the violation. Criminal records further restrict future business opportunities and regulatory trust.
- Fines and monetary penalties: Heavy fines are imposed for each instance of selling unapproved products. The penalty amount varies based on product type, scale of distribution, and risk to public health. Repeat offenders face escalating fines, sometimes exceeding several lakhs of rupees. Financial penalties are designed to deter non‑compliance and encourage lawful practices. These fines add to the overall cost burden, alongside legal fees and operational losses.
- Reputational and market impact: Public disclosure of violations severely damages consumer trust in the brand. Healthcare professionals and distributors may refuse to engage with non‑compliant companies. Competitors gain advantage as customers shift to approved and trusted alternatives. International partners may terminate contracts due to regulatory non‑compliance. Long‑term reputational harm can outweigh immediate financial penalties, making recovery difficult.
How can regulatory consultants help you avoid regulatory consequences of selling products without CDSCO approval?
- Expert guidance on licensing: Regulatory consultants understand the exact forms, procedures, and authorities involved in CDSCO licensing. They ensure companies apply for the correct license based on product type. This prevents errors or omissions that could delay approval or trigger penalties. By securing proper licenses upfront, companies avoid illegal manufacturing or import activities.
- Risk assessment and compliance audits: Consultants conduct gap analyses to identify areas where a company may be non‑compliant. They review documentation, labeling, and quality systems against CDSCO standards. This proactive approach helps businesses correct issues before regulators discover them.
- Efficient documentation and submission: Regulatory filings often fail due to incomplete or incorrect documentation. Consultants prepare dossiers, technical files, and quality certifications in line with CDSCO requirements. They streamline submissions, reducing back‑and‑forth with authorities.
- Training and awareness for teams: Consultants train staff on CDSCO rules, licensing requirements, and compliance practices. Training reduces accidental violations caused by ignorance of regulations.
- Strategic liaison with regulators: Consultants act as intermediaries between companies and CDSCO officials. They clarify queries, respond to objections, and negotiate timelines effectively. This professional liaison reduces miscommunication and regulatory friction.
Email at [email protected] or call/Whatsapp on 9996859227 to hire us as your trusted regulatory consultant to avoid the consequences of selling products without CDSCO approval. We have expertise in the pharmaceutical, medical devices, and cosmetics regulatory domains.
